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WHONET: An Information
System for Monitoring
Antimicrobial Resistance
WHONET is an information system developed to
support The World Health Organization’s (WHO)
goal of global surveillance of bacterial resistance to
antimicrobial agents. Microbiologists, clinicians and
infection control workers may use its software to
enhance monitoring of drug resistance in their hos-
pitals and communities and to merge their files into
national, regional, and global networks for surveil-
lance of drug resistance. WHONET software can be
installed on personal computers and be configured
for the locations of the patients a laboratory serves
and for the antimicrobial agents it tests. The pro-
gram accepts susceptibility test results and allows
printing of reports and logbooks and retrieval of
data. If the laboratory already has a computerized
reporting system, a translation program can be cre-
ated to download the laboratory’s files into
WHONET. Either way, the microbiologists and other
infectious disease specialists gain new analytical
tools to monitor and manage susceptibility test qual-
ity and the spread of drug resistance locally and
outside their area.
WHONET can also analyze stored data. From a
single screen, a WHONET user selects the type of
analysis to run, the species of bacteria to analyze,
the subsets of isolates to include (e.g., all, isolates
from urine only, and isolates resistant to gentamicin
and from certain locations), and the antimicrobial
agents and period to examine. Types of analyses
include percentage of data categorized as resistant,
intermediate, or susceptible by standard or other
breakpoints; distributions of test measurements
(zone diameter, minimal inhibitory concentration) in
the form of histograms; scatterplots comparing
measurements for different agents or methods for
the same isolates; and line listings of isolates
grouped by combinations of agents to which they are
resistant (antibiotypes) to trace distinctive strains.
Isolates with uncommon antibiotypes can also be
flagged on entry so that they may be rechecked while
still available, and local outbreaks can be detected early.
Although test results are entered and monitored
locally on software configured for local use, they are
filed in a universal file format so that any copy of the
program can analyze the files of any laboratory. This
feature has enabled groups of users in 10 countries
to set up passive surveillance systems by pooling and
analyzing their files collaboratively. WHONET as-
sists such initiatives by providing file encryption
options to ensure confidentiality before data are
pooled and analyzed.
Ongoing local analysis by local workers is the
foundation of the system. It detects local problems
in testing, which no laboratory can avoid entirely,
and thus improves the overall quality of the files. It
delineates local spread of drug-resistant strains,
which aids infection control and can explain and
correct uncommon prevalence of certain types of
drug resistance at certain sites. It allows local work-
ers to distinguish their problems from those of other
sites and focus on infection control or antimicrobial
use that might be related to those problems.
Expansion of the system has been recommended
by the WHO Scientific Working Group on Monitor-
ing and Management of Bacterial Resistance to An-
timicrobial Agents. For more  information or for
participation contact 
Thomas F. O’Brien and John M. Stelling
WHO Collaborating Center for Surveillance of
Resistance to Antimicrobial Agents
Microbiology, Brigham and Women’s Hospital
Boston, MA 02115, USA
tel (1-617) 732-6803
fax (1-617) 732-4144
Internet: whonet@bustoff.bwh.harvard.edu
Recommendations for
Preventing the Spread of
Vancomycin Resistance
CDC’s Hospital Infection Control Practices Advi-
sory Committee (HICPAC) has published “Recom-
mendations for Preventing the Spread of
Vancomycin Resistance.” The recommendations fo-
cus on vancomycin-resistant enterococci (VRE).
The reported incidence of infection and coloniza-
tion with VRE in U.S. hospitals has increased rap-
idly in the last 5 years. This increase has
compounded the need for antimicrobial drugs to
treat VRE infections. Most VRE are also resistant to
multiple other drugs (e.g., aminoglycoside and am-
picillin), which have been used for treating VRE
infections. In addition, the possibility that the van-
comycin-resistance genes present in VRE may be
transferred to other gram-positive microorganisms,
especially Staphylococcus aureus, is a serious public
health concern.
Although the epidemiology of VRE has not been
fully elucidated, and most enterococcal infections
have been attributed to the patient’s endogenous
flora, recent studies have demonstrated that entero-
cocci, including VRE, can be spread directly from
patient to patient or indirectly by transient carriage
on the hands of personnel or contaminated environ-
mental surfaces and patient-care equipment.
In its recommendations, HICPAC stresses that
the prevention and control of vancomycin resistance
will require a coordinated, concerted effort from
various departments of a hospital. Because the rec-
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